Sage Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Sage Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sage Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sage Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Sage Therapeutics Inc (Sage Therapeutics) is a biopharmaceutical company focused on developing medicines for brain health disorders. The company primarily targets the central nervous system (CNS) receptor systems, specifically GABA and NMDA receptors, to address neuropsychiatric and neurodevelopmental disorders. Sage Therapeutics operates in the biopharmaceutical industry, with a focus on developing treatments for conditions such as postpartum depression (PPD) and major depressive disorder (MDD).
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D activities focus on the allosteric modulation of the GABA A and NMDA receptor systems in the brain, targeting potential treatments for neurodevelopmental disorders with compounds such as SAGE-817 and SAGE-039. The company’s R&D activities are focused therapy areas such as central nervous system (CNS), dementia, epilepsy, Parkinson’s Disease, postpartum depression, and major depressive disorder. The company leverages its proprietary chemistry platform to design molecules with improved selectivity, tolerability, and fewer off-target side effects. The company is also involved in co-development and co-manufacturing activities with Biogen, particularly for the licensed 217 and 324 products in the US Sage Therapeutics Inc has reprioritized its pipeline development efforts and anticipates cost savings from the 2024 Restructuring, which included a significant reduction in its workforce. Sage Therapeutics is testing SAGE-718 in neurodegenerative disorders such as Huntington's, Alzheimer's, and Parkinson's. In FY2024, the company spent US$225.9 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer